Veracyte Inc (NAS:VCYT)
$ 42.49 -0.92 (-2.12%) Market Cap: 3.29 Bil Enterprise Value: 3.11 Bil PE Ratio: 0 PB Ratio: 2.80 GF Score: 80/100

Veracyte Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 07:30PM GMT
Release Date Price: $25.12 (+0.80%)
Edmund Tu
Morgan Stanley, Research Division - Research Associate

(technical difficulty)

health care conference. My name is Edmund Tu, and I'm on the life science tools and diagnostics team here at Morgan Stanley. I'm very pleased to have Bonnie Anderson, the CEO of Veracyte, with me onstage today.

And before we begin, I just want to remind everyone that all disclosures that are relevant to this conversation can be found on our disclosure web page at morganstanley.com\researchdisclosures (sic) [morganstanley.com/researchdisclosures].

So Bonnie, thank you for coming today. I have a series of questions prepared for you, but I think it'd be a good idea to start off on a very high level and remind all investors what your company does if you would.

Bonnie H. Anderson
Veracyte, Inc. - Co-Founder, Chairman & CEO

That sounds great. Thank you, first of all, for the opportunity to be here at the Morgan Stanley Healthcare Conference.

Yes. So Veracyte is at a pretty exciting place with our business. We were founded about 11

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot